10/13/2022
Santiago Garcia, MD; Anastasios Milkas, MD, PhD; Byeong-Keuk Kim, MD, PhD; M. Nicholas Burke, MD; Nidal Abi Rafeh, MD; Jaikirshan J. Khatri, MD; Lorenzo Azzalini, MD, PhD, MSc; Kevin J. Croce, MD, PhD; Michael S. Megaly, MD, MS; Khaldoon Alaswad, MD; Amirali Masoumi, MD; Wissam A. Jaber, MD; Kambis Mashayekhi, MD; William J. Nicholson, MD; Margaret B. McEntegart, MD, PhD, BSc(Hons), MBChB; Andrea Gagnor, MD; Seung-Whan Lee, MD, PhD; Georgios Sianos, MD, PhD; Scott A. Harding, MD, RT(R)(CV); Dimitrios Karmpaliotis, MD, PhD; Alexandre Avran, MD, PhD; Yangsoo Jang, MD, PhD; Emmanouil S. Brilakis, MD, PhD, FACC, FAHA, FESC, FSCAI; Farouc A. Jaffer, MD, PhD; Darshan Doshi, MD, MS; Judit Karacsonyi, MD, PhD; Etsuo Tsuchikane, MD, PhD; Bahadir Simsek, MD; Hsien-Li Kao, MD; Bavana V. Rangan, BDS, MPH, MD; Carlo Di Mario, MD, PhD, FESC, FACC, FRCP; Spyridon Kostantinis, MD; Roberto Garbo, MD; Alfredo Ruggero Galassi, MD; Paul Poommipanit, MD, FACC, FSCAI; Khalid O. Tammam, MD, PhD; Gerald S. Werner, MD, PhD; Evangelia Vemmou, MD; Masahisa Yamane, MD, PhD; Eugene B. Wu, MD, DM; Ilias Nikolakopoulos, MD; Stéphane Rinfret, MD, SM; Paul Knaapen, MD, PhD
Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) can improve patient symptoms, but it remains controversial whether it impacts subsequent clinical outcomes.
Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) can improve patient symptoms, but it remains controversial whether it impacts subsequent clinical outcomes.
Chronic total occlusion (CTO)...